4.6 Review

Targeting Myosin by Blebbistatin Derivatives: Optimization and Pharmacological Potential

Journal

TRENDS IN BIOCHEMICAL SCIENCES
Volume 43, Issue 9, Pages 700-713

Publisher

ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tibs.2018.06.006

Keywords

-

Funding

  1. Hungarian National Research, Development and Innovation Office Grant [NVKP 16-1-2016-0051]

Ask authors/readers for more resources

Blebbistatin is a widely used inhibitor of myosin 2 that enables the study of a broad range of cytoskeleton-related processes. However, blebbistatin has several limitations hindering its applicability: it is fluorescent, poorly water soluble, cytotoxic, and prone to (photo)degradation. Despite these adverse effects, being the only available myosin 2-specific inhibitor, blebbistatin is rather a choice of necessity. Blebbistatin has been modified to improve its properties and some of the new compounds have proven to be useful replacements of the original molecule. This review summarizes recent results on blebbistatin development. We also discuss the pharmacological perspectives of these efforts, as myosins are becoming promising drug target candidates for a variety of conditions ranging from neurodegeneration to muscle disease, wound healing, and cancer metastasis.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available